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Hepatitis E virus (HEV) is an important cause of
jaundice in developing countries in tropical and
subtropical regions. The virus is transmitted via
the fecal-oral route, although the possibility for
zoonotic acquisition of HEV infection has been sug-
gested by several studies.1,2
Lemos et al., in a seroprevalence survey, demon-
strated that HEV could have been responsible for a
considerable number of sporadic viral hepatitis epi-
sodes inCubanpatients.3 InAugust2003a22-year-old
man living in a suburb of Havana City was admitted to
the gastroenterology service of the Pedro Kourı´ Insti-
tute. He had not previously traveled abroad and had
had no contact with people who had recently arrived
from other countries. The patient did not have a
history of jaundice, blood transfusion, tattoos or
intravenousdruguse.He reported14days of anorexia
and general malaise before progressively developingFigure 1 Reverse transcription-polymerase chain reac-
tion amplification products of Cuban HEV strain. Lane 1
and 5, molecular weight marker (100 bp); lane 2, positive
control; lane 3, stool sample from Cuban patient; lane 4,
negative control.
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was negative for hepatitis A virus IgM antibodies;
hepatitis B surface antigen; hepatitis B core antibody
and hepatitis C virus antibodies using commercially
available kits. Laboratory results of initial tests
included alanine aminotransferase (ALAT) 103 UI/L;
aspartate aminotransferase (ASAT) 144 UI/L, biliru-
bin 49 mmol/L and alkaline phosphatase 75 UI/L.
Liver and gall bladder appeared normal on abdominal
ultrasound. The retest of serum samples one week
later revealed a diminution of ALAT (65 UI/L) and a
minimal decrease of ASAT (110 UI/L). The biochem-
ical recovery was not complete until six months
after the onset of the signs and symptoms of viral
hepatitis. Acute stage serum was HEV IgM antibody
positive (MBC/AMRAD Hepatitis E IgM Diagnostic
Kit, Macfarlane Institute, Australia), with sample
optical density/cut off ratio (1.337/0.305) greater
than 1, according to the manufacturer’s recommen-
dation. HEV IgG antibody levels rose over several
determinations, which provided strong evidence
of acute HEV infection (MBC/AMRAD Hepatitis E
IgG Diagnostic Kit, Macfarlane Institute, Australia).
Genome particles of HEV were detected in stool
samples using primers described by Schlauder and
coworkers.4 (Figure 1).
In Latin America, studies on HEV have been car-
ried out in Argentina, Brazil, Mexico, and Vene-
zuela.5—8 This report indicates that HEV should be
taken into account in sporadic cases of viral hepa-
titis diagnosed in Cuba. Further investigations are
needed in order to establish antigenic and genotypic
characteristic of the Cuban HEV strain. This is the
first clinical, virological and epidemiological report
on acute hepatitis E in a Cuban patient.
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